PMS-IPRATROPIUM SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

IPRATROPIUM BROMIDE

متاح من:

PHARMASCIENCE INC

ATC رمز:

R03BB01

INN (الاسم الدولي):

IPRATROPIUM BROMIDE

جرعة:

250MCG

الشكل الصيدلاني:

SOLUTION

تركيب:

IPRATROPIUM BROMIDE 250MCG

طريقة التعاطي:

INHALATION

الوحدات في الحزمة:

1ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANTIMUSCARINICS ANTISPASMODICS

ملخص المنتج:

Active ingredient group (AIG) number: 0115643001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

1997-04-25

خصائص المنتج

_pms-IPRATROPIUM Product Monograph Page 1 of 28_
PRODUCT MONOGRAPH
PR
PMS-IPRATROPIUM
Ipratropium Bromide Inhalation Solution
125 mcg/mL & 250 mcg/mL
BRONCHODILATOR
PHARMASCIENCE INC.
6111 Royalmount Avenue, Suite 100
Montreal, Quebec H4P 2T4
www.pharmascience.com
Date of Revision:
April 12, 2017
Control No: 197460
_pms-IPRATROPIUM Product Monograph Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................14
SPECIAL HANDLING INSDTUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
..........................................................................16
CLINICAL TRIALS
................